Interleukin-6

Critical Care Medicine

Volumn 33, Issue 12 SUPPL., 2005, Pages

  Song, Mingchen ^a   Kellum, John A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CARDIOTROPHIN 1; CCAAT ENHANCER BINDING PROTEIN; CILIARY NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GLYCOPROTEIN GP 130; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; TUMOR NECROSIS FACTOR;

B LYMPHOCYTE; CELL DIFFERENTIATION; CHROMOSOME 7; CRITICAL ILLNESS; CYTOKINE PRODUCTION; EMBRYONIC STEM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GENE MAPPING; HEMATOPOIETIC CELL; HYPOPHYSIS; INTRON; KNOCKOUT MOUSE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SEPSIS; T LYMPHOCYTE;

EID: 28944445444     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000186784.62662.A1     Document Type: Article

References (19)

1. Weissenbach J, Chernajovsky Y, Zeevi M, et al: Two interferon mRNAs in human fibroblasts: In vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A 1980; 77:7152-7156
2. Waage A, Brandtzaeg P, Halstensen A, et al: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169:333-338
3. Helfgott DC, Tatter SB, Santhanam U, et al: Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. J Immunol 1989; 142:948-953
4. Kishimoto T, Akira S, Narazaki M, et al: Interleukin-6 family of cytokines and gp130. Blood 1995; 86:1243-1254
5. Fong Y, Moldawer LL, Marano M, et al: Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol 1989; 142:2321-2324
6. Patel RT, Deen KI, Youngs D, et al: Interleukin 6 is a prognostic indicator of outcome in severe intra- abdominal sepsis. Br J Surg 1994; 81:1306-1308
7. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
8. Barriere SL, Lowry SF: An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23:376-393
9. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
10. Calandra T, Baumgartner JD, Grau GE, et al: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990; 161:982-987
11. Marano MA, Fong Y, Moldawer LL, et al: Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Cynecol Obstet 1990; 170:32-38
12. Yang R, Han X, Uchiyama T, et al: IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol 2003; 285:G621-G629
13. Bernardo A, Ball C, Nolasco L, et al: Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multimers under flow. Blood 2004; 104:100-106
14. Vanden Berghe W, Vermeulen L, De Wilde G: Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000; 60:1185-1195
15. van der Poll T, Levi M, Hack CE, et al: Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179:1253-1259
16. Derhaschnig U, Bergmair D, Marsik C, et al: Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med 2004; 32:1136-1140
17. Brundage SI, Zautke NA, Halcomb JB, et al: Interleukin-6 infusion blunts proinflammatory cytokine production without causing systematic toxicity in a swine model of uncontrolled hemorrhagic shock. J Trauma 2004; 57:970-978
18. Wu X, Prueckner S, Rollwagen F, et al: Gut damage during hemorrhagic shock: Effects on survival of oral or enterai interleukin-6. Shock 2001; 16:449-453
19. Panacek EA, Marshall JC, Albertson TE, et al: Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182